Promoted Content Promoted Content

X

Market Place

Market Place

Menu

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Prices
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Xenon Pharmaceuticals Inc

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              CANADA Canada

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Virtual Innovation Day

              Participation Not Confirmed

              Update your events

              Xenon Pharmaceuticals Announces Pricing of $100.0 Million Public Offering

              Contact the Supplier

              Lead Product(s): Ezogabine

              Therapeutic Area: Neurology Product Name: XEN496

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Jefferies

              Deal Size: $100.0 million Upfront Cash: Undisclosed

              Deal Type: Public Offering March 09, 2021

              Details:

              XEN496, a Kv7 potassium channel modulator that is a proprietary pediatric formulation of the active ingredient ezogabine being developed for the treatment of KCNQ2 developmental and epileptic encephalopathy (KCNQ2-DEE).

              Orion Biotechnology

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              CANADA Canada

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Virtual Innovation Day

              Participation Not Confirmed

              Update your events

              Orion’s Phase 3 REFALS Trial Evaluating Oral Levosimendan in Treatment of ALS Patients Did Not Reach its Pre-Specified Endpoints

              Contact the Supplier

              Lead Product(s): Levosimendan

              Therapeutic Area: Neurology Product Name: ODM-109

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 28, 2020

              Details:

              The primary endpoint of the trial was to show a statistically significant difference between levosimendan and placebo in slow vital capacity (SVC) in supine position at 12 weeks compared to the baseline.

              PharmaCompass__DigitalAd